about
Geographical Variation and Factors Associated with Non-Small Cell Lung Cancer in Manitoba.The treatment of metastatic non-small cell lung cancer in the elderly: an evidence-based approachChallenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare SystemChemoradiotherapy versus radiotherapy alone in elderly patients with stage III non-small cell lung cancer: A systematic review and meta-analysis.Brain metastases in non-small-cell lung cancer.Assessment of Referral and Chemotherapy Treatment Patterns for Elderly Patients With Non-small-Cell Lung Cancer.Health-related quality of life following operative treatment of unstable ankle fractures: a prospective observational study.The effect of statin use on the incidence of prostate cancer: A population-based nested case-control study.Immune Signatures of Non-Small Cell Lung Cancer.Cigarette smoke decreases pulmonary dendritic cells and impacts antiviral immune responsiveness.The effect of age on referral to an oncologist and receipt of chemotherapy among small cell lung cancer patients in Ontario, CanadaMethods to improve the estimation of time-to-event outcomes when data is de-identifiedAssociation of interleukin-6 and interleukin-8 with poor prognosis in elderly patients with chronic lymphocytic leukemiaNever too old to learn new tricks: surveying Canadian health care professionals about learning needs in caring for older adults with cancerImmunotherapy with check-point inhibitors (CPI) in adult malignancies: a protocol for the systematic review of the quality of economic analyses.Androgen Receptor and Ki67 Expression and Survival Outcomes in Non-small Cell Lung CancerMitochondrial Respiration Correlates with Prognostic Markers in Chronic Lymphocytic Leukemia and Is Normalized by Ibrutinib TreatmentAssessing the learning needs of the multidisciplinary team on geriatric oncology and frailtyThe use of chemotherapy in older patients with stage II and III colon cancer: Variation by age and era of diagnosisScoping review protocol documenting cancer outcomes and inequalities for adults living with intellectual and/or developmental disabilitiesDescriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centreBenefit of crizotinib in a lung cancer patient with discordant ALK testing resultsNivolumab-Induced Secondary Sclerosing Cholangitis with Deterioration Despite Immunosuppression
P50
Q33877570-D419D0E0-888F-4234-A794-3414B4E0D961Q33878770-6591C441-A395-4E0A-BE41-E4335F690A12Q34608597-3F64AC1A-057D-44C2-B40D-0774C76687C2Q36114671-7D4D3C5B-A0F8-487C-BB6A-B3D543A9321BQ38222356-6900CC30-5D97-46E7-B179-D65125A214CBQ39635219-0E76CC61-850A-471A-AA5E-7AA9BECA90AEQ44949239-DF1F7150-9B7F-41FA-9F37-BF62594164F0Q48100185-D4526AD4-80CB-4679-8009-2F6E9B78F9E2Q50201376-25DE1BD9-1E9C-4AD4-927E-F11FD466FBF8Q51658663-C3B7F5CB-13D4-4B50-B13B-DD8BE4877C3FQ57476188-E4BF8058-A336-4123-835E-9EDB97F54B73Q57477376-0FE93C93-DCBA-4B87-B539-B0ADBB0571E9Q58436696-0C9BC757-8067-427C-BC7B-90671D221778Q64091012-1AB6AD33-0E9C-44E3-A0D3-FFAF1BD0157CQ64898823-AF3BAE90-8728-4192-BB3A-0A0020F5B050Q89145660-27990832-4132-491B-A128-FC79B7CE9629Q90307292-8173FE9D-1880-405A-8026-ABE4D32B43C6Q90804590-D651C6B1-6B0F-4DC3-AC11-02CE3D20583AQ90925925-01A4DB65-137A-429B-AA3C-C0535765F428Q91104189-86133E79-DDBF-4ECE-9887-35F9422C1891Q91217003-B1CA9C95-AA85-49C3-BE74-55966F4EB15DQ91399334-C5722209-9DD1-433C-8D78-9EA9476D8355Q92843721-A5C89DFE-2A9D-4B9F-A376-FD5BDDF9C1BF
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David E Dawe
@ast
David E Dawe
@en
David E Dawe
@es
David E Dawe
@nl
type
label
David E Dawe
@ast
David E Dawe
@en
David E Dawe
@es
David E Dawe
@nl
prefLabel
David E Dawe
@ast
David E Dawe
@en
David E Dawe
@es
David E Dawe
@nl
P106
P1153
7005658738
P21
P31
P496
0000-0001-9762-3156